Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160907 | 0.90 | GRM5 (0.39) | CYP2C19HSD17B10NPSR1ALDH1A1P2RX3 | |
| SCHEMBL5158788 | 0.87 | MEN1 (0.33) | MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL5158887 | 0.86 | — | — | |
| SCHEMBL5160991 | 0.86 | CYP1A2 (0.39) | CYP2C19MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL5162728 | 0.82 | CYP3A4 (0.34) | CYP2C19MEN1KMT2AHTTHSD17B10 | |
| SCHEMBL5158793 | 0.78 | — | — | |
| SCHEMBL5156930 | 0.78 | CYP2C19 (0.33) | CYP2C19CYP2C9NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL5156483 | 0.77 | CYP1A2 (0.38) | CYP2C19NPSR1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL5156290 | 0.77 | P2RX3 (0.32) | P2RX3 | |
| SCHEMBL5161670 | 0.77 | XDH (0.34) | MEN1KMT2AHTTHSD17B10NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135468-A1 | PYRIDYLOXYALKANOIC ACID AMIDE DERIVATIVES USEFUL AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2007-06-14 | — | — | US | disclosed |
| EP-1456174-B1 | PYRIDYLOXYALKANOIC ACID AMIDE DERIVATIVES USEFUL AS FUNGICIDES | SYNGENTA LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-7166621-B2 | Pyridyloxyalkanoic acid amide derivatives useful as fungicides | SYNGENTA LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20050065032-A1 | Pyridyloxyalkanoic acid amide derivatives useful as fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2005-03-24 | — | — | US | disclosed |
| EP-1456174-A1 | PYRIDYLOXYALKANOIC ACID AMIDE DERIVATIVES USEFUL AS FUNGICIDES | Syngenta Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003048128-A1 | PYRIDYLOXYALKANOIC ACID AMIDE DERIVATIVES USEFUL AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065032-A1 | Pyridyloxyalkanoic acid amide derivatives useful as fungicides | DDT, C3AR1, CNPY3 | CYP2C19 842/4885CYP2C9 244/4885MEN1 1481/4885 |
| US-20070135468-A1 | PYRIDYLOXYALKANOIC ACID AMIDE DERIVATIVES USEFUL AS FUNGICIDES | DDT, C3AR1, CBR3 | CYP2C19 658/4885CYP2C9 189/4885MEN1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.